1,721,115 research outputs found
Body weight and food intake in Parkinson’s disease: A review of the association to non-motor symptoms.
No full textResearch on eating behaviours has extensively highlighted that cognitive systems interact with the met- abolic system in driving food intake and in influencing body weight regulation. Parkinson’s disease is a good model for studying these complex interactions since alterations in both body weight and cogni- tive domains have been frequently reported among these patients. Interestingly, even if different non- motor symptoms may characterize the course of the disease, their contribution to weight and food preference has been poorly investigated. This review describes body weight alterations and eating habits in patients with Parkinson’s disease, including those who underwent deep brain stimulation surgery. In particular, the review considers the link between non-motor symptoms, affecting sensory perception, cognition, mood and motivation, and food intake and weight alterations. The take home message is twofold. First, we recommend a comprehensive approach in order to develop effective strategies in the manage- ment of patients’ weight. Second, we also suggest that investigating this issue in patients with Parkinson’s disease may provide some useful information about the mechanisms underlying food and weight reg- ulation in healthy subjects
Deep brain stimulation in the management of multiple sclerosis tremor
No full textMultiple sclerosis can be associated with action tremor in 50%-75% of patients. Medical treatment usually does not provide adequate long-term tremor suppression. Deep brain stimulation of the ventro-infero-medial nucleus of the thalamus can provide a dramatic, although temporary, suppression of the tremor, but a limited number of patients are available for surgical treatment. © Springer-Verlag Italia 2006
A population-based study of injuries to the brachial plexus and to the peripheral nerves of the shoulder girdle and upper limb in the Italian region Friuli Venezia Giulia
No full textThe aim of this study was to estimate the incidence, identify the causes, and explore treatments of the injuries to the brachial plexus and peripheral nerves of the shoulder girdle and upper limb in the 1,220,000-inhabitant Italian region Friuli Venezia Giulia.We linked at the individual patient level various administrative databases using an anonymous stochastic key: list of residents, hospital discharge, emergency department, and outpatient care prescriptions database. We abstracted hospital discharge records with at least one discharge diagnosis code ICD-9-CM 953.4 (brachial plexus) or 955.0-955.9 (upper limb). For hospitalized patients, we investigated the prescriptions of ambulatory care during the following year. Emergency department visits in the month prior to hospital admission were also assessed.From 2000 to 2015, we observed 474 hospitalizations (annual average: 61); 48% of patients received at least one prescription of outpatient physical therapy and rehabilitation in the following year, accounting for more than 25,000 visits and interventions. According to emergency department data, falls were the most common mechanism among the elderly; cuts were common among the young.This is the first population study of peripheral nerve injuries to the brachial plexus and peripheral nerves of the shoulder girdle and upper limb in Italy
Clinical duration of action of different botulinum toxin types in humans
Full text linkThe Botulinum NeuroToxin (BoNT) comprises several serotypes with distinct properties, mechanisms of action, sensitivity and duration of effect in different species. The serotype A (BoNT/A) is the prevalent neurotoxin applied in human's disease. In this paper we present an overview of the current knowledge regarding the duration of effect and the neuromuscular sprouting of different BoNT serotypes in humans. Then, we report the original results of a study in healthy subjects treated with BoNT/A, B, C and F using different neurophysiological techniques. Twelve healthy volunteers (7 men, 5 women) are treated with BoNT/A, B, C and F or placebo in Abductor digiti minimi (ADM) muscle of the hand. Before and after injections, an extensive neurophysiological study is performed with the CMAP amplitude variation, Multi-Motor Unit Action Potentials (MUAPs) analysis, the Turns/Amplitude ratio of interference pattern (IP) and determination of jitter and Fiber Density (FD) at single-fiber electromyography (SFEMG), at week 2 (w2), 4 (w4), 6 (w6) and 8 (w8). A maximal neuromuscular block is obtained at w2 for all the serotypes. Afterwards, the CMAP trend appear similar for BoNT/A, B, and C while, BoNT/F shows a faster recover. Multi-MUAPs analysis and IP detect mild changes at w2 for all serotypes, except for BoNT/F that shows a greater change since w4. SFEMG have minimal changes in FD while, Jitter increase at w2 with a slower decrease over the time for all BoNTs. In conclusion, BoNT/F has earlier sprouting and complete recovery at w8. Other serotypes present a slower and similar profile. The EMG appear useful to study the functional recovery in humans, and these results should provide new evidence for assessing different serotypes. These findings improve our knowledge regarding the methods to evaluate duration of effects and dose equivalents in different serotypes, that in the future could change the clinicians strategy for disease-tailored BoNT therapies
Cognitive and brain reserve for mind-body therapeutic approaches in multiple sclerosis: A review
No full textPurpose: Cognitive impairment is one of the most disabling symptoms of multiple sclerosis (MS), affecting a large proportion of
patients and having a severe impact on their quality of life. Nevertheless, there exists a large variability in the neuropsychological
profiles of MS patients and some of them appear to withstand better than others the MS-related brain pathology before showing
cognitive decline. In recent years, many studies have made use of concepts such as cognitive reserve and brain reserve to take
account of the inter-individual discrepancy between cognitive impairment and MS pathology. Critically, these studies have left
open the fundamental issue of the clinical implications of this research for the treatment of cognitive dysfunction in MS.
Methods and Results:We provide an updated and extensive overviewof the studies that have explored cognitive and brain reserve
in MS and discuss their implications for non-pharmacological therapeutic strategies aimed at potentiating patients’ reserve. In
particular, the possible utility of integrated approaches based on mind-body techniques such as mindfulness-meditation is
considered. Conclusions: We conclude that these techniques represent challenging mental enriching activities that may help cultivating
cognitive reserve and more systematic research on their efficacy to protect against cognitive degradation in MS is encouraged
Different types of botulinum toxin in humans
No full textIn humans, botulinum neurotoxin (BoNT) serotype A (BoNT/A) is a useful therapeutic tool, but different BoNT serotypes may be useful when a specific immune resistance related to BoNT/A is proved. BoNT serotype F (BoNT/F) was injected into human muscles but its effects are shorter compared to BoNT/A, whereas BoNT serotype B (BoNT/B) is effective in humans only if injected at very high doses. BoNT serotype C (BoNT/C) has a general profile of action similar to BoNT/A. Nevertheless, a comparison between these different BoNTs in human has not yet been reported. To establish the general profile of these different BoNTs in humans and the spread in near and untreated muscles we conducted an electrophysiological evaluation in 12 healthy volunteers by injecting BoNT/A (BOTOX 15MU), BoNT/B (NeuroBloc 1500MU), BoNT/F (15MU), BoNT/C (15MU) and a saline solution (placebo) in the abductor digiti minimi muscle (ADM) in a double-blind manner. The compound muscle action potential (CMAP) amplitude variation, before and at 2, 4, 6 and 8 weeks after the injections, was evaluated in the ADM, the fourth dorsal interosseus, the first dorsal interosseus and the abductor pollicis brevis APB. We detected an earlier recovery for BoNT/F when compared to the other BoNTs. No significant differences in the local or distant BoNT spread was observed among the different serotypes. We conclude that in humans, BoNT/B and BoNT/C have a general profile similar to BoNT/A and as such these serotypes could be alternative therapies to BoNT/A. BoNT/F might be useful when only a short duration of neuromuscular blockade is required
The botulinum toxin treatment of lower facial muscles in patients affected by hemifacial spasm
No full textPrecision Medicine in Parkinson’s Disease: From Genetic Risk Signals to Personalized Therapy
No full textUnderstanding the pathophysiology and genetic background of Parkinson’s disease (PD) increases the likelihood of developing effective disease-modifying therapeutic strategies. In particular, the discovery of genetic variants causing or increasing the risk for PD has contributed to refining the clinical, biological, and molecular classification of the disease and has offered new insights into sporadic forms. It is even more evident that specific genetic mutations can show different responses to pharmacological and device-aided therapies. To date, several agents acting on multiple PD-causing pathogenic pathways have been tested as disease-modifying strategies, with disappointing results. This may be caused by the recruitment of PD populations whose underlying molecular pathophysiology is heterogeneous. We believe that an effective model of personalized medicine must be prioritized in the near future. Here, we review the current therapeutic options under clinical and preclinical development for PD and discuss the key pending questions and challenges to face for successful clinical trials. Furthermore, we provide some insights into the role of genetics in guiding the decision-making process on symptomatic and device-aided therapies for PD in daily clinical practice
- …
